巨子生物宣布，其旗下子公司已正式获得中国国家药品监督管理局（NMPA）颁发的医疗器械注册证书，产品涉及重组胶原蛋白与透明质酸钠溶液。
这一重要资质的获取，标志着公司在医美材料领域的技术实力与合规水平获得官方认可，为后续市场拓展奠定坚实基础。
随着医美行业监管趋严，具备正规资质的优质产品有望迎来更广阔的发展空间。此次获批也将进一步巩固巨子生物在生物材料领域的领先地位。
巨子生物宣布，其旗下子公司已正式获得中国国家药品监督管理局（NMPA）颁发的医疗器械注册证书，产品涉及重组胶原蛋白与透明质酸钠溶液。
这一重要资质的获取，标志着公司在医美材料领域的技术实力与合规水平获得官方认可，为后续市场拓展奠定坚实基础。
随着医美行业监管趋严，具备正规资质的优质产品有望迎来更广阔的发展空间。此次获批也将进一步巩固巨子生物在生物材料领域的领先地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.